Polatuzumab vedotin - Genentech

Drug Profile

Polatuzumab vedotin - Genentech

Alternative Names: anti-CD79b-VC-MMAE; DCDS-4501A; FCU-2711; RG-7596; RO-5541077; RO-5541077-000

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 01 Aug 2018 Chugai Pharmaceutical plans a phase II trial for Diffuse large B-cell lymphoma (Combination therapy, Recurrent, Second-line therapy) in Japan (JapicCTI184048)
  • 01 Jun 2018 Efficacy and safety data from a phase I/II trial in Diffuse large B-cell lymphoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Diffuse large B cell lymphoma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top